Global Gene Therapy for Age-related Macular Degeneration Market Research Report 2023

Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD. AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.

The global Gene Therapy for Age-related Macular Degeneration market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

It has been observed that age-related macular degeneration (AMD) is one of the major causes for vision loss and is characterized by the formation of a blurred area near the center of vision, a condition that mostly affects the geriatric population. According to the CDC, almost 2 million individuals in the US suffer from AMD and by 2050, this number will reach more than 5 million. This will subsequently demand the need for the development of innovative treatments for AMD, driving the market's growth.

This report aims to provide a comprehensive presentation of the global market for Gene Therapy for Age-related Macular Degeneration, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapy for Age-related Macular Degeneration.

The Gene Therapy for Age-related Macular Degeneration market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Gene Therapy for Age-related Macular Degeneration market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Gene Therapy for Age-related Macular Degeneration companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Subretinal

1.2.3 Intravitreal

1.3 Market by Application

1.3.1 Global Gene Therapy for Age-related Macular Degeneration Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Monotherapy

1.3.3 Combination Therapy

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Gene Therapy for Age-related Macular Degeneration Market Perspective (2018-2029)

2.2 Gene Therapy for Age-related Macular Degeneration Growth Trends by Region

2.2.1 Global Gene Therapy for Age-related Macular Degeneration Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Gene Therapy for Age-related Macular Degeneration Historic Market Size by Region (2018-2023)

2.2.3 Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Region (2024-2029)

2.3 Gene Therapy for Age-related Macular Degeneration Market Dynamics

2.3.1 Gene Therapy for Age-related Macular Degeneration Industry Trends

2.3.2 Gene Therapy for Age-related Macular Degeneration Market Drivers

2.3.3 Gene Therapy for Age-related Macular Degeneration Market Challenges

2.3.4 Gene Therapy for Age-related Macular Degeneration Market Restraints

3.1 Global Top Gene Therapy for Age-related Macular Degeneration Players by Revenue

3.1.1 Global Top Gene Therapy for Age-related Macular Degeneration Players by Revenue (2018-2023)

3.1.2 Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Players (2018-2023)

3.2 Global Gene Therapy for Age-related Macular Degeneration Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Gene Therapy for Age-related Macular Degeneration Revenue

3.4 Global Gene Therapy for Age-related Macular Degeneration Market Concentration Ratio

3.4.1 Global Gene Therapy for Age-related Macular Degeneration Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Gene Therapy for Age-related Macular Degeneration Revenue in 2022

3.5 Gene Therapy for Age-related Macular Degeneration Key Players Head office and Area Served

3.6 Key Players Gene Therapy for Age-related Macular Degeneration Product Solution and Service

3.7 Date of Enter into Gene Therapy for Age-related Macular Degeneration Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Gene Therapy for Age-related Macular Degeneration Historic Market Size by Type (2018-2023)

4.2 Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Type (2024-2029)

5.1 Global Gene Therapy for Age-related Macular Degeneration Historic Market Size by Application (2018-2023)

5.2 Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Application (2024-2029)

6.1 North America Gene Therapy for Age-related Macular Degeneration Market Size (2018-2029)

6.2 North America Gene Therapy for Age-related Macular Degeneration Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023)

6.4 North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Gene Therapy for Age-related Macular Degeneration Market Size (2018-2029)

7.2 Europe Gene Therapy for Age-related Macular Degeneration Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023)

7.4 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size (2018-2029)

8.2 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2018-2023)

8.4 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Gene Therapy for Age-related Macular Degeneration Market Size (2018-2029)

9.2 Latin America Gene Therapy for Age-related Macular Degeneration Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023)

9.4 Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size (2018-2029)

10.2 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023)

10.4 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 RetroSense Therapeutics

11.1.1 RetroSense Therapeutics Company Detail

11.1.2 RetroSense Therapeutics Business Overview

11.1.3 RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Introduction

11.1.4 RetroSense Therapeutics Revenue in Gene Therapy for Age-related Macular Degeneration Business (2018-2023)

11.1.5 RetroSense Therapeutics Recent Development

11.2 REGENXBIO

11.2.1 REGENXBIO Company Detail

11.2.2 REGENXBIO Business Overview

11.2.3 REGENXBIO Gene Therapy for Age-related Macular Degeneration Introduction

11.2.4 REGENXBIO Revenue in Gene Therapy for Age-related Macular Degeneration Business (2018-2023)

11.2.5 REGENXBIO Recent Development

11.3 AGTC

11.3.1 AGTC Company Detail

11.3.2 AGTC Business Overview

11.3.3 AGTC Gene Therapy for Age-related Macular Degeneration Introduction

11.3.4 AGTC Revenue in Gene Therapy for Age-related Macular Degeneration Business (2018-2023)

11.3.5 AGTC Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Subretinal

    Table 3. Key Players of Intravitreal

    Table 4. Global Gene Therapy for Age-related Macular Degeneration Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 5. Global Gene Therapy for Age-related Macular Degeneration Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 6. Global Gene Therapy for Age-related Macular Degeneration Market Size by Region (2018-2023) & (US$ Million)

    Table 7. Global Gene Therapy for Age-related Macular Degeneration Market Share by Region (2018-2023)

    Table 8. Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 9. Global Gene Therapy for Age-related Macular Degeneration Market Share by Region (2024-2029)

    Table 10. Gene Therapy for Age-related Macular Degeneration Market Trends

    Table 11. Gene Therapy for Age-related Macular Degeneration Market Drivers

    Table 12. Gene Therapy for Age-related Macular Degeneration Market Challenges

    Table 13. Gene Therapy for Age-related Macular Degeneration Market Restraints

    Table 14. Global Gene Therapy for Age-related Macular Degeneration Revenue by Players (2018-2023) & (US$ Million)

    Table 15. Global Gene Therapy for Age-related Macular Degeneration Market Share by Players (2018-2023)

    Table 16. Global Top Gene Therapy for Age-related Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for Age-related Macular Degeneration as of 2022)

    Table 17. Ranking of Global Top Gene Therapy for Age-related Macular Degeneration Companies by Revenue (US$ Million) in 2022

    Table 18. Global 5 Largest Players Market Share by Gene Therapy for Age-related Macular Degeneration Revenue (CR5 and HHI) & (2018-2023)

    Table 19. Key Players Headquarters and Area Served

    Table 20. Key Players Gene Therapy for Age-related Macular Degeneration Product Solution and Service

    Table 21. Date of Enter into Gene Therapy for Age-related Macular Degeneration Market

    Table 22. Mergers & Acquisitions, Expansion Plans

    Table 23. Global Gene Therapy for Age-related Macular Degeneration Market Size by Type (2018-2023) & (US$ Million)

    Table 24. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Type (2018-2023)

    Table 25. Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 26. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Type (2024-2029)

    Table 27. Global Gene Therapy for Age-related Macular Degeneration Market Size by Application (2018-2023) & (US$ Million)

    Table 28. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Application (2018-2023)

    Table 29. Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 30. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Application (2024-2029)

    Table 31. North America Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 32. North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023) & (US$ Million)

    Table 33. North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029) & (US$ Million)

    Table 34. Europe Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 35. Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023) & (US$ Million)

    Table 36. Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029) & (US$ Million)

    Table 37. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 38. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2018-2023) & (US$ Million)

    Table 39. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2024-2029) & (US$ Million)

    Table 40. Latin America Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 41. Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023) & (US$ Million)

    Table 42. Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029) & (US$ Million)

    Table 43. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 44. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023) & (US$ Million)

    Table 45. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029) & (US$ Million)

    Table 46. RetroSense Therapeutics Company Detail

    Table 47. RetroSense Therapeutics Business Overview

    Table 48. RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Product

    Table 49. RetroSense Therapeutics Revenue in Gene Therapy for Age-related Macular Degeneration Business (2018-2023) & (US$ Million)

    Table 50. RetroSense Therapeutics Recent Development

    Table 51. REGENXBIO Company Detail

    Table 52. REGENXBIO Business Overview

    Table 53. REGENXBIO Gene Therapy for Age-related Macular Degeneration Product

    Table 54. REGENXBIO Revenue in Gene Therapy for Age-related Macular Degeneration Business (2018-2023) & (US$ Million)

    Table 55. REGENXBIO Recent Development

    Table 56. AGTC Company Detail

    Table 57. AGTC Business Overview

    Table 58. AGTC Gene Therapy for Age-related Macular Degeneration Product

    Table 59. AGTC Revenue in Gene Therapy for Age-related Macular Degeneration Business (2018-2023) & (US$ Million)

    Table 60. AGTC Recent Development

    Table 61. Research Programs/Design for This Report

    Table 62. Key Data Information from Secondary Sources

    Table 63. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Gene Therapy for Age-related Macular Degeneration Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Gene Therapy for Age-related Macular Degeneration Market Share by Type: 2022 VS 2029

    Figure 3. Subretinal Features

    Figure 4. Intravitreal Features

    Figure 5. Global Gene Therapy for Age-related Macular Degeneration Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 6. Global Gene Therapy for Age-related Macular Degeneration Market Share by Application: 2022 VS 2029

    Figure 7. Monotherapy Case Studies

    Figure 8. Combination Therapy Case Studies

    Figure 9. Gene Therapy for Age-related Macular Degeneration Report Years Considered

    Figure 10. Global Gene Therapy for Age-related Macular Degeneration Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 11. Global Gene Therapy for Age-related Macular Degeneration Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 12. Global Gene Therapy for Age-related Macular Degeneration Market Share by Region: 2022 VS 2029

    Figure 13. Global Gene Therapy for Age-related Macular Degeneration Market Share by Players in 2022

    Figure 14. Global Top Gene Therapy for Age-related Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for Age-related Macular Degeneration as of 2022)

    Figure 15. The Top 10 and 5 Players Market Share by Gene Therapy for Age-related Macular Degeneration Revenue in 2022

    Figure 16. North America Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 17. North America Gene Therapy for Age-related Macular Degeneration Market Share by Country (2018-2029)

    Figure 18. United States Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 19. Canada Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 20. Europe Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 21. Europe Gene Therapy for Age-related Macular Degeneration Market Share by Country (2018-2029)

    Figure 22. Germany Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 23. France Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 24. U.K. Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 25. Italy Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. Russia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. Nordic Countries Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Share by Region (2018-2029)

    Figure 30. China Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Japan Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 32. South Korea Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 33. Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. India Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. Australia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. Latin America Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. Latin America Gene Therapy for Age-related Macular Degeneration Market Share by Country (2018-2029)

    Figure 38. Mexico Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. Brazil Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 40. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 41. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Share by Country (2018-2029)

    Figure 42. Turkey Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 43. Saudi Arabia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 44. RetroSense Therapeutics Revenue Growth Rate in Gene Therapy for Age-related Macular Degeneration Business (2018-2023)

    Figure 45. REGENXBIO Revenue Growth Rate in Gene Therapy for Age-related Macular Degeneration Business (2018-2023)

    Figure 46. AGTC Revenue Growth Rate in Gene Therapy for Age-related Macular Degeneration Business (2018-2023)

    Figure 47. Bottom-up and Top-down Approaches for This Report

    Figure 48. Data Triangulation

    Figure 49. Key Executives Interviewed